A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma

Objectives Immunotherapy with immune checkpoint inhibitors has shown only limited success in the management of metastatic soft tissue sarcoma. Overall response rates (ORR) with single agent pembrolizumab were 18% and median PFS was 18 weeks on the clinical trial SARC028. One strategy to improve the...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jeremy P. Harris MD, MPhil, Jino Park MD, Eric Ku MD, Steven Seyedin MD, Russell Stitzlein MD, Amanda Goldin MD, Wen-Pin Chen MS, Christine McLaren PhD, Allen M. Chen MD, Warren Chow MD
Format:	Artigo
Idioma:	Inglês
Publicat:	SAGE Publishing 2024-02-01
Col·lecció:	Cancer Control
Accés en línia:	https://doi.org/10.1177/10732748241237331
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!